回顾适用于肥胖症的药物再利用。

避免过度肥胖，肥胖可能增加多种癌症风险 #生活知识# #科技生活# #健康生活技巧# #癌症#

回顾适用于肥胖症的药物再利用。

IF 8 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM

引用次数: 0

摘要

肥胖症是一个重大的公共卫生问题，也是个人和医疗系统的负担。由于调整生活方式所面临的挑战和局限性，建议考虑对肥胖症患者进行药物治疗。然而，现有药物的副作用和有限疗效使得肥胖症药物市场远远不够。药物再利用包括为现有药物寻找新的应用领域，与传统的药物开发方法相比，它具有成本低、开发时间短等优势。本综述旨在概述抗肥胖药物的再利用，包括再利用的理由、挑战和方法，以及正在进行再利用研究的潜在药物。通过先进的计算技术，研究人员可以发掘再利用药物的潜力，解决全球肥胖症流行的问题。进一步的研究、临床试验和合作努力对于充分探索和利用药物再利用在对抗肥胖症方面的潜力至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

A review on drug repurposing applicable to obesity

Obesity is a major public health concern and burden on individuals and healthcare systems. Due to the challenges and limitations of lifestyle adjustments, it is advisable to consider pharmacological treatment for people affected by obesity. However, the side effects and limited efficacy of available drugs make the obesity drug market far from sufficient. Drug repurposing involves identifying new applications for existing drugs and offers some advantages over traditional drug development approaches including lower costs and shorter development timelines. This review aims to provide an overview of drug repurposing for anti-obesity medications, including the rationale for repurposing, the challenges and approaches, and the potential drugs that are being investigated for repurposing. Through advanced computational techniques, researchers can unlock the potential of repurposed drugs to tackle the global obesity epidemic. Further research, clinical trials, and collaborative efforts are essential to fully explore and leverage the potential of drug repurposing in the fight against obesity.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。 去求助

来源期刊

CiteScore

19.30

自引率

1.10%

发文量

130

审稿时长

1 months

期刊介绍： Obesity Reviews is a monthly journal publishing reviews on all disciplines related to obesity and its comorbidities. This includes basic and behavioral sciences, clinical treatment and outcomes, epidemiology, prevention and public health. The journal should, therefore, appeal to all professionals with an interest in obesity and its comorbidities. Review types may include systematic narrative reviews, quantitative meta-analyses and narrative reviews but all must offer new insights, critical or novel perspectives that will enhance the state of knowledge in the field. The editorial policy is to publish high quality peer-reviewed manuscripts that provide needed new insight into all aspects of obesity and its related comorbidities while minimizing the period between submission and publication.

0

相关文献

二甲双胍通过HDAC6和FoxO3a转录调控肌肉生长抑制素诱导肌肉萎缩

IF 8.9 1区 医学

Min Ju Kang, Ji Wook Moon, Jung Ok Lee, Ji Hae Kim, Eun Jeong Jung, Su Jin Kim, Joo Yeon Oh, Sang Woo Wu, Pu Reum Lee, Sun Hwa Park, Hyeon Soo Kim

具有疾病敏感单倍型的非亲属供体脐带血移植后的1型糖尿病

IF 3.2 3区 医学

Kensuke Matsumoto, Taisuke Matsuyama, Ritsu Sumiyoshi, Matsuo Takuji, Tadashi Yamamoto, Ryosuke Shirasaki, Haruko Tashiro

网址：回顾适用于肥胖症的药物再利用。 https://www.yuejiaxmz.com/news/view/856962

相关内容

适合肥胖症患者的16道食疗方
胡乱减肥等于自残 吃减肥药减的不是“肥”
肥胖症患者的饮食小建议
肥胖症的膳食预防与控制
《肥胖症诊疗指南（2024年版）》发布
柳叶刀重磅综述：成人肥胖症的现代医学疗法
国家级肥胖症诊疗指南来了，提醒GLP
儿童肥胖症会带来哪些不良影响？
肥胖+糖尿病=糖胖症，预防和治疗糖胖症需要考虑减少炎症
小讲课｜肥胖

随便看看